<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Losartan; Valsartan; Candesartan; Irbesartan; Angiotensin-II receptor antagonists; Antihypertensives: angiotensin-II receptor antagonists; Azilsartan; Eprosartan; Olmesartan; Telmisartan" /><meta name="IX" content="Losartan; Valsartan; Candesartan; Irbesartan; Angiotensin-II receptor antagonists; Antihypertensives: angiotensin-II receptor antagonists; Azilsartan; Eprosartan; Olmesartan; Telmisartan" /><title>2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1205-angiotensin-ii-receptor-antagonists.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP1205-angiotensin-ii-receptor-antagonists.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1205-angiotensin-ii-receptor-antagonists.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a> &gt; <a href="PHP1034-hypertension-and-heart-failure.htm">2.5 Hypertension and heart failure</a> &gt; <a href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm">2.5.5 Drugs affecting the renin-angiotensin system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1198-trandolapril.htm" title="Previous: TRANDOLAPRIL">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP18478-azilsartan-medoxomil.htm" title="Next: AZILSARTAN MEDOXOMIL">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>2.5.5.2 </span>Angiotensin-II receptor antagonists</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a>).</p></div></div><p><strong>Azilsartan, candesartan</strong>, <strong>eprosartan</strong>, <strong>irbesartan</strong>, <strong>losartan</strong>, <strong>olmesartan</strong>, <strong>telmisartan</strong>, and <strong>valsartan</strong> are angiotensin-II receptor antagonists with many properties similar to those of the ACE inhibitors. However, unlike ACE inhibitors, they do not inhibit the breakdown of bradykinin and other kinins, and thus are less likely to cause the persistent dry cough which can complicate ACE inhibitor therapy. They are therefore a useful alternative for patients who have to discontinue an ACE inhibitor because of persistent cough.</p><p>An angiotensin-II receptor antagonist may be used as an alternative to an ACE inhibitor in the management of heart failure (<a title="sub-section: Drugs affecting the renin-angiotensin system" href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm">section 2.5.5</a>) or diabetic nephropathy (<a title="sub-section: Treatment of diabetic nephropathy and neuropathy" href="PHP4232-treatment-of-diabetic-nephropathy-and-neuropathy.htm">section 6.1.5</a>).</p><div id="PHP1206"><h2>Cautions</h2><p>Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, <a title=" Angiotensin-converting enzyme inhibitors" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm">section 2.5.5.1</a>). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. <strong>Interactions:</strong> Appendix 1 (angiotensin-II receptor antagonists).</p> </div><div id="PHP1207"><h2>Pregnancy</h2><p>Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported.</p></div><div id="PHP1208"><h2>Breast-feeding</h2><p>Information on the use of angiotensin-II receptor antagonists in breast-feeding is limited. They are not recommended in breast-feeding and alternative treatment options, with better established safety information during breast-feeding, are available. </p></div><div><h2>Side-effects</h2><p id="PHP18489">Side-effects are usually mild. Symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high-dose diuretics). Hyperkalaemia occurs occasionally; angioedema has also been reported with some angiotensin-II receptor antagonists.</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP18478-azilsartan-medoxomil"><a href="PHP18478-azilsartan-medoxomil.htm" title="AZILSARTAN MEDOXOMIL">AZILSARTAN MEDOXOMIL</a></li><li id="_PHP1209-candesartan-cilexetil"><a href="PHP1209-candesartan-cilexetil.htm" title="CANDESARTAN CILEXETIL">CANDESARTAN CILEXETIL</a></li><li id="_PHP1211-eprosartan"><a href="PHP1211-eprosartan.htm" title="EPROSARTAN">EPROSARTAN</a></li><li id="_PHP1213-irbesartan"><a href="PHP1213-irbesartan.htm" title="IRBESARTAN">IRBESARTAN</a></li><li id="_PHP1219-losartan-potassium"><a href="PHP1219-losartan-potassium.htm" title="LOSARTAN POTASSIUM">LOSARTAN POTASSIUM</a></li><li id="_PHP1227-olmesartan-medoxomil"><a href="PHP1227-olmesartan-medoxomil.htm" title="OLMESARTAN MEDOXOMIL">OLMESARTAN MEDOXOMIL</a></li><li id="_PHP1239-telmisartan"><a href="PHP1239-telmisartan.htm" title="TELMISARTAN">TELMISARTAN</a></li><li id="_PHP1245-valsartan"><a href="PHP1245-valsartan.htm" title="VALSARTAN">VALSARTAN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1198-trandolapril.htm">Previous: TRANDOLAPRIL</a> | <a class="top" href="PHP1205-angiotensin-ii-receptor-antagonists.htm#">Top</a> | <a accesskey="]" href="PHP18478-azilsartan-medoxomil.htm">Next: AZILSARTAN MEDOXOMIL</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>